A total of 21 patients were treated in a phase I trial using the biological response modifier MVE-2, a low molecular weight component of pyran copolymer. All patients received weekly IV MVE-2 infused over 2 h. Proteinuria, sometimes of nephrotic proportions, was the dose limiting toxicity, and was seen with increasing incidence as the cumulative dose of MVE-2 exceeded 2500 mg. Other toxicity with MVE-2 was minimal. Biologic response modification at tolerable doses was inconsistent, although several assays, particularly natural cell-mediated cytotoxicity, indicated enhanced activity at higher dosages of MVE-2. No objective tumor responses were observed. MVE-2 is not useful as a biological response modifier using our initial method of administration, since the dose limiting toxicity occurred at lower levels than were necessary to induce consistent biologic response modification. Following completion of the phase I study, we administered MVE-2 by 30-min infusion to 8 additional patients and did not detect proteinuria, in spite of large cumulative doses. It is possible that alternate schedules of MVE-2 administration could minimize proteinuria and allow the administration of dosages necessary for immunologic modification.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Breslow BS, Edwards EK, Newberg NR (1973) Divinyl ethermaleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity. Nature 246:160–162
Dean JH, Connon R, Herberman RB, Silva J, et al. (1977) The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens. Int J Cancer 20:359–370
Dean JH, Padarathsingh ML, Keys L (1978) Response of murine leukemia to combined BCNU-maleic anhydride-vinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay. Cancer Treat Rep 62:1807–1816
Djeu J, Payne S, Alford C, Heim W, et al. (1977) Detection of decreased proportion of lymphocytes forming rosettes with sheep erythrocytes at 29 °C in the blood of cancer patients. Analysis of factors affecting the assay. Clin Immunol Immunopathol 8:405–419
Forbes JT, Niblack GD, Fuchs R, Richie RE, et al. (1981) Human natural cell-mediated cytotoxicity. I. Levels in peripheral blood, cord blood, and thoracic duct lymphocytes. Cancer Immunol Immunother 11:139–145
Forbes JT, Greco FA, Oldham RK (1981) Human natural cell-mediated cytotoxicity II. Activity in cancer patients. Cancer Immunol Immunother 11:147–153
Forbes JT, Luck A, Greco FA (1982) Modification of human natural cell-mediated cytotoxicity by MVE-2. In: Herberman R (ed) NK cells and other natural effector cells. Academic Press, New York
Levin AC, Massey RJ, Deinhardt F (1978) Spontaneous human mononuclear cell cytotoxicity to cultured tumor cells: Reproducibility of serial measurement with use of a chromium-51-release microcytotoxicity assay. J Natl Cancer Inst 60:1283–1289
Merigan TC (1967) Induction of circulating interferon by synthetic amonic polymers of known composition. Nature 214:416–417
Morahan PS, Barnes DW, Munson AE (1978) Relationship of molecular weight to antiviral and antitumor activities and toxic effect of maleic anhydride-divinylether (MVE) polyanions. Cancer Treat Rep 62:1977–1983
Paulidis NA, Schultz RM, Chirigos MA, Luetzeler J (1978) Effect of maleic anhydride-divinylether copolymers on 109 experimental metastases and macrophage tumoricidal function. Cancer Treat Rep 62:1817–1822
Pearson JW, Chirigos MA, Chaparas SD, Sher NA (1974) Combined drug and immunostimulation therapy against a syngeneic murine leukemia. J Natl Cancer Inst 52:463–468
Rinehart JJ, Young DC, Neidhart JA (1983) Evaluation of the immunological and toxicological properties of MVE-2 in phase I trials. Cancer Res 43:2358–2362
Supported in part by National Institutes of Health grants CA 23477, CA 27333, Contract NO1 CM07438, and by a grant from Adria Laboratories
About this article
Cite this article
Hainsworth, J.D., Forbes, J.T., Grosh, W.W. et al. Phase I study of MVE-2 evaluating toxicity and biologic response modification capability. Cancer Immunol Immunother 22, 68–71 (1986). https://doi.org/10.1007/BF00205719
- Tumor Response
- Cumulative Dose
- Additional Patient